NYSE:AORT Artivion (AORT) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free AORT Stock Alerts $23.85 +2.78 (+13.19%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$22.86▼$25.5150-Day Range$18.58▼$23.8552-Week Range$12.16▼$25.51Volume939,369 shsAverage Volume221,221 shsMarket Capitalization$982.62 millionP/E RatioN/ADividend YieldN/APrice Target$23.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Artivion alerts: Email Address Artivion MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.3% Upside$27.50 Price TargetShort InterestBearish7.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 16 Articles This WeekInsider TradingSelling Shares$2.89 M Sold Last QuarterProj. Earnings Growth123.08%From $0.26 to $0.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector654th out of 903 stocksSurgical & Medical Instruments Industry73rd out of 95 stocks 2.5 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 2 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.16% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently decreased by 1.41%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 2.6 News and Social Media Coverage News SentimentArtivion has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Artivion this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,891,627.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow by 123.08% in the coming year, from $0.26 to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -31.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -31.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About Artivion Stock (NYSE:AORT)Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More AORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Stock News HeadlinesMay 7, 2024 | markets.businessinsider.comBreaking Down Artivion: 4 Analysts Share Their ViewsMay 7, 2024 | msn.comArtivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call TranscriptMay 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 7, 2024 | finance.yahoo.comArtivion Inc (AORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)May 7, 2024 | msn.comAORT Stock Earnings: Artivion Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | uk.finance.yahoo.comArtivion Inc (AORT) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceMay 6, 2024 | prnewswire.comArtivion Reports First Quarter 2024 Financial ResultsMay 7, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 4, 2024 | americanbankingnews.comArtivion (AORT) Scheduled to Announce Quarterly Earnings on MondayApril 30, 2024 | msn.comAtriCure Q1 2024 Earnings PreviewApril 30, 2024 | finance.yahoo.comArtivion presents double win at AATS for aortic devicesApril 29, 2024 | prnewswire.comArtivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual MeetingApril 22, 2024 | prnewswire.comArtivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial ResultsApril 19, 2024 | finance.yahoo.comArtivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last yearApril 1, 2024 | finance.yahoo.comArtivion to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | investing.comArtivion's VP regulatory sells shares worth over $29kMarch 17, 2024 | uk.investing.comArtivion VP regulatory sells shares worth $79,880March 16, 2024 | uk.investing.comArtivion executive sells shares worth nearly $100kMarch 6, 2024 | prnewswire.comArtivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 21, 2024 | finance.yahoo.comWall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a BetFebruary 16, 2024 | finance.yahoo.comArtivion, Inc. (NYSE:AORT) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | msn.comArtivion (AORT) Surpasses Q4 Earnings and Revenue EstimatesFebruary 15, 2024 | finance.yahoo.comArtivion Inc (AORT) Reports Solid Revenue Growth and Robust EBITDA Increase in Q4 and Full Year 2023February 15, 2024 | finance.yahoo.comArtivion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | prnewswire.comArtivion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comAORT Apr 2024 12.500 putSee More Headlines Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/07/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,500Year FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside-1.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E Ratio91.73 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-8.67% Pretax Margin-6.10% Return on Equity3.02% Return on Assets1.09% Debt Debt-to-Equity Ratio1.10 Current Ratio4.85 Quick Ratio3.43 Sales & Book Value Annual Sales$354 million Price / Sales2.78 Cash Flow$0.88 per share Price / Cash Flow27.24 Book Value$6.87 per share Price / Book3.47Miscellaneous Outstanding Shares41,200,000Free Float37,863,000Market Cap$982.62 million OptionableOptionable Beta1.66 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James Patrick Mackin (Age 57)Chairman, President & CEO Comp: $2.37MMs. Amy D. Horton CPA (Age 54)VP & Chief Accounting Officer Comp: $621.26kMs. Jean F. Holloway Esq. (Age 67)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $841.43kMr. John E. Davis (Age 59)Senior VP & Chief Commercial Officer Comp: $802.02kMr. Matthew A. Getz (Age 55)VP of Human Resources & Chief Human Resources Officer Dr. Marshall S. Stanton M.D. (Age 67)Senior VP of Clinical Research & Chief Medical Officer Comp: $615.55kDr. Robert C. Thomson (Age 54)Vice President of Research & Development Mr. Florian TyrsVice President of Global OperationsMore ExecutivesKey CompetitorsParagon 28NYSE:FNASilk Road MedicalNASDAQ:SILKAtrionNASDAQ:ATRIMiMedx GroupNASDAQ:MDXGOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsIllinois Municipal Retirement FundSold 695 shares on 5/7/2024Ownership: 0.055%Texas Permanent School Fund CorpBought 677 shares on 5/6/2024Ownership: 0.083%BNP Paribas Financial MarketsBought 8,715 shares on 5/1/2024Ownership: 0.048%Mirae Asset Global Investments Co. Ltd.Sold 1,133 shares on 5/1/2024Ownership: 0.040%Allspring Global Investments Holdings LLCBought 4,154 shares on 4/30/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions AORT Stock Analysis - Frequently Asked Questions Should I buy or sell Artivion stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AORT shares. View AORT analyst ratings or view top-rated stocks. What is Artivion's stock price target for 2024? 2 brokers have issued 1-year target prices for Artivion's shares. Their AORT share price targets range from $25.00 to $30.00. On average, they anticipate the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts. How have AORT shares performed in 2024? Artivion's stock was trading at $17.88 at the start of the year. Since then, AORT stock has increased by 33.4% and is now trading at $23.85. View the best growth stocks for 2024 here. When is Artivion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AORT earnings forecast. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Monday, May, 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.04. The business earned $97.43 million during the quarter, compared to analyst estimates of $92.30 million. Artivion had a negative net margin of 8.67% and a positive trailing twelve-month return on equity of 3.02%. During the same quarter last year, the company earned $0.02 earnings per share. What ETFs hold Artivion's stock? ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC), Invesco S&P SmallCap Health Care ETF (PSCH) and Unusual Whales Subversive Democratic Trading ETF (NANC).iShares U.S. Medical Devices ETF (IHI). What guidance has Artivion issued on next quarter's earnings? Artivion updated its FY 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $386.0 million-$396.0 million, compared to the consensus revenue estimate of $388.0 million. Who are Artivion's major shareholders? Artivion's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (2.63%), Principal Financial Group Inc. (0.54%), New York State Teachers Retirement System (0.18%), Texas Permanent School Fund Corp (0.08%), Illinois Municipal Retirement Fund (0.05%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Marshall S Stanton, Matthew A Getz and Rochelle L Maney. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AORT) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.